Oral Obesity Therapies Market Report 2026

The oral obesity therapies market size has grown strongly in recent years. It will grow from $3.94 billion in 2025 to $4.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing global obesity prevalence, rising awareness of metabolic health risks, expansion of prescription-based weight management drugs, growth in clinical research on appetite regulation mechanisms, increasing healthcare focus on non-invasive obesity treatments.

The oral obesity therapies market size is expected to see strong growth in the next few years. It will grow to $6.32 billion by 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to rising adoption of oral glp-1 therapies, increasing demand for personalized metabolic treatments, growth in telemedicine-based obesity care, expansion of next-generation oral incretin drugs, rising investment in obesity drug pipelines by pharma companies. Major trends in the forecast period include rising adoption of oral glp-1 based therapies for appetite regulation and weight management, increasing use of combination oral obesity drugs targeting multiple metabolic pathways, growing demand for personalized obesity treatment based on genetic and metabolic profiling, expansion of telehealth enabled prescription access for oral weight loss therapies, rising development of gut hormone modulating oral drugs for improved metabolic control.

The increasing prevalence of obesity is expected to drive the growth of the oral obesity therapies market going forward. Obesity refers to a medical condition characterized by excessive accumulation of body fat that elevates the risk of health conditions such as heart disease, diabetes, and hypertension. Obesity is increasing mainly due to greater consumption of calorie-dense processed foods, which results in excess energy intake and gradual weight gain when not balanced with physical activity. Oral obesity therapies help manage obesity by regulating hunger-related hormones and reducing calorie absorption, contributing to sustained weight management and improved health outcomes. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, during 2023-2024, the prevalence of overweight conditions, including obesity, among adults was higher in men (69.7%) than in women (59.2%), while obesity alone was slightly more common in women (26.9%) compared to men (26.2%). Therefore, the increasing prevalence of obesity is driving the growth of the oral obesity therapies market.

Leading companies operating in the oral obesity therapies market are focusing on developing innovative solutions such as incretin-based therapy to improve weight loss efficacy, enhance metabolic outcomes, and provide convenient non-injectable treatment options for patients. Incretin-based therapy refers to a class of treatments that mimic or enhance the action of incretin hormones, such as GLP-1, to regulate blood sugar levels, suppress appetite, and support weight loss. For instance, in January 2026, Novo Nordisk, a Denmark-based healthcare company, launched an LP-1 pill for obesity called the Wegovy pill (oral semaglutide) for chronic weight management in adults with obesity or overweight alongside related conditions, in combination with diet and exercise. It was also approved to reduce cardiovascular risks such as heart attacks and strokes in individuals with established heart disease.

In December 2023, Hoffmann-La Roche AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics Inc. for $2.7 billion. Through this acquisition, Roche aims to strengthen its position in the obesity and metabolic disease segment by expanding its portfolio of incretin-based therapies, including oral GLP-1 drug candidates, and improving its drug development capabilities. Carmot Therapeutics Inc. is a US-based biotechnology company that provides oral obesity therapies.

Major companies operating in the oral obesity therapies market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Sun Pharmaceutical Industries Ltd., Jiangsu Hengrui Medicine Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Hanmi Pharmaceutical Co. Ltd., Innovent Biologics Inc., Viking Therapeutics Inc., Rhythm Pharmaceuticals Inc., Septerna Therapeutics, Eccogene Inc., Currax Pharmaceuticals LLC, Ascletis Pharma Inc., Structure Therapeutics.

North America was the largest region in the oral obesity therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral obesity therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oral obesity therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral obesity therapies market consists of sales of prescription oral anti-obesity drugs, over-the-counter weight management tablets, appetite suppressants, fat absorption inhibitors, and metabolic enhancers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.